Effects of Quetiapine on Ultrastructural Hippocampal and Neurochemical Changes in Patients With Bipolar Disorder: Searching for Antidepressant and Mood Stabilising Neurophysiology

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study was to determine the pharmacological induced equivalents of neurogenesis and synaptic sprouting in the hippocampus, localized volume changes, changes in water content and neurochemical changes in the medial temporal regions.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: RWTH Aachen University
• Treatments: Antidepressive Agents; Quetiapine Fumarate

Criteria

Inclusion Criteria:

• age ranging 18 - 55 years old

• intelligence coefficient (IQ) of minimum 85 as estimated by MWT-B

• MRI compatibility

• for healthy volunteers - no DSM-IV diagnosis

• patients should have had a diagnosis of bipolar disorder in accordance with DSM-IV.

Exclusion Criteria:

• substances or alcohol abuse or dependence (except caffeine and nicotine) at enrollment;

• medical conditions that would affect absorption, distribution, metabolism or excretion of study treatment;

• unstable or inadequately treated medical illness (diabetes, angina, pectoris, hypertension);

• diabetes mellitus

• patients who in the opinion of the investigator pose a risk of suicide or danger to self or others,

• patients who known intolerance or lack of response to Quetiapine fumarate,

• patients who use of any of the cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, nelfinavir, ritonavir, fluvoxamine and saquinavir) in the 14 days preceding enrollment,

• patients who use of any of the cytochrome P450 inducers (phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort and glucocorticoids) in the 14 days preceding enrollment,

• current treatment of Quetiapine or use of mood stabilizer or antidepressant as co-medication throughout the study.

• lack of inform consent